THE DEAL, AT A GLANCE

APTADIR

4/4 reviewed

APTADIR

Aptadir develops RNA medicines to switch silenced genes back on for genetic diseases and cancers.

Aptadir announced a €40 million seed round closed on September 29, 2026.

01What it doesAptadir develops RNA medicines to switch silenced genes back on for genetic diseases and cancers.Source-grounded · automated review · Explore ↗

Checked 2026-10-01 · Review due 2026-10-08

Read supporting source ↗

Aptadir Therapeutics is a preclinical…

02Who is involved4BIO Capital led, with follow-on participation from original pre-seed investor EXTEND.Source-grounded · automated review · Explore ↗

Checked 2026-10-01 · Review due 2026-10-08

Read supporting source ↗

The round was led by…

03What happenedAptadir announced a €40 million seed round closed on September 29, 2026.Source-grounded · automated review · Explore ↗

Checked 2026-10-01 · Review due 2026-10-08

Read supporting source ↗

On September 29, 2026 Aptadir…

04Why it mattersThe funding moves CAP1-FMR1, a Fragile X treatment candidate, toward clinical testing.Interpretation · Explore ↗

Checked 2026-10-01 · Review due 2026-10-08

Read supporting source ↗

CAP1-FMR1 is the lead candidate,…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

APTADIR · Financing Record

Explore source-linked visual explanations for APTADIR. Unsupported claims are withheld while source review continues.

Record 13055 · Recorded date: 2026-09-29

Open record 13055 →